From early planning to literature research, AI tools are already being used in market access workflows. Watch this short expert insight from Dr Stefan Walzer and find out where they add real value — and where caution is needed.
What the expert says
In a CELforPharma educational webinar, Dr Stefan Walzer shared a practical overview of how open-access AI platforms can be used at different stages of the product lifecycle. The key message: these tools can be genuinely useful, but knowing how to prompt them — and when to trust the output — is what makes the difference.
"If you ask, for example, give me the incidence and prevalence for a given disease, out of 10 answers you get at least six different ones. That is why we normally say: early, fast, quick-and-dirty results — for that, ChatGPT versions are quite fine."
Dr Stefan Walzer, CEO, MArS Market Access and Pricing Strategy · CELforPharma webinar
| 👥 | Quick descriptions of patient populations and mechanisms of action | 💊 | Overviews of current treatment options in a given indication |
| 📘 | Clarifications on EMA and FDA guidelines | 🔍 | Targeted searches for studies, GBA decisions, and NICE reports via Perplexity |
| 📑 | Clinical evidence searches via Evidence Hunt | 🔒 | Secure internal GPTs for tasks involving confidential data |
| ⚠️ | Open-access tools are best suited to early-stage, exploratory work where no confidential information is involved. For tasks involving confidential data, many larger companies have already implemented secure internal GPT environments for this purpose. | ||
Continue your learning about AI in Market Access
If you’d like to learn more from Stefan, CELforPharma also offers a 2-day, hands-on course:
The AI for Pharma Market Access Course
With Dr Stefan Walzer
Don’t miss the latest insights from our expert faculty
Subscribe to our newsletter to:
- Stay on top of the latest expert insights
- Receive invitations to upcoming educational webinars
- Get updates on our courses and training programmes